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Abstract Therapeutic regulation of tissue vascularization
has appeared as an attractive approach to treat a number of
human diseases. In vivo neovascularization assays that
reflect physiological and pathological formation of neo-
vessels are important in this effort. In this report we present
an assay where the effects of activators and inhibitors of
angiogenesis can be quantitatively and qualitatively mea-
sured. A provisional matrix composed of collagen I and
fibrin was formed in a plastic cylinder and implanted onto
the chick chorioallantoic membrane. A nylon mesh sepa-
rated the implanted matrix from the underlying tissue to
distinguish new from pre-existing vessels. Vascularization
of the matrix in response to fibroblast growth factor-2 or
platelet-derived growth factor-BB was scored in a double-
blinded manner, or vessel density was measured using a
semi-automated image analysis procedure. Thalidomide,
fumagillin, U0126 and TGFb inhibited neovessel growth
while hydrocortisone exerted a negative and wortmannin a
toxic effect on the pre-existing vasculature. This quantita-
tive, inexpensive and rapid in vivo angiogenesis assay
might be a valuable tool in screening and characterizing
factors that influence wound or tumor induced vasculari-
zation and in assessing their effects on the normal
vasculature.
Keywords Angiogenesis  Animal model  In vivo 
Chick chorioallantoic membrane  Drug screening 
Wound healing  Tumor
Introduction
Expansion of the capillary bed by angiogenesis is in the
healthy adult limited to wound healing, physiological
growth of tissues (e.g. fat, skeletal muscle) and cyclic
variations in the endometrium and the corpus luteum [2, 3].
Increased or aberrant angiogenesis is seen in a number of
diseases such as tumor growth, proliferative retinopathies,
rheumatoid arthritis and psoriasis [4–6]. Failure to restore
proper organ function in conditions such as chronic wounds
and in ischemic diseases of the heart or brain might be due
to insufficient angiogenesis during tissue regeneration
[7, 8]. Consequently, therapies that either inhibit or stim-
ulate vascularization could offer new treatment options for
a variety of diseases and both strategies have been explored
in clinical trials [8–11]. A humanized anti-VEGF antibody
has thus been approved for use in combination with stan-
dard chemotherapy for metastatic colon cancer, metastatic
non-squamous non-small-cell lung cancer, metastatic renal
cell carcinoma (RCC) and as monotherapy for recur-
rent glioblastoma multiforme [4, 12, 13]. However, other
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anti-angiogenic drug candidates showed no or limited
effects on tumor growth in clinical trials despite promising
effects in pre-clinical experiments e.g. the matrix
metalloproteinase inhibitors marimastat [14] and batimas-
tat [15], the shark cartilage extract Neovastat [16] and the
avb3 and avb5 inhibitors S36578 and cilengitide [17, 18].
It is therefore important to acknowledge limitations in
existing experimental models, including in vivo angio-
genesis assays, in order to define cellular and molecular
mechanisms that regulate tissue vascularization and to
identify suitable therapeutic targets.
The optimal in vivo angiogenesis assay should permit
absolute quantitative measurements of vascular ingrowth,
give a clear distinction between newly formed and pre-
existing vessels, allow non-invasive monitoring and be
cost-effective, rapid, reproducible and reliable [19–23].
The growth of vessels during ontogenesis has been exten-
sively studied using the chick chorioallantoic membrane
(CAM) [24, 25], the mouse retina [26] and the zebra fish
[27]. However, conclusions derived from developmental
models cannot be directly translated into post-embryonic
wound healing or tumor vascularization since these pro-
cesses are driven by different mechanisms [28, 29].
Developmental vascularization is a genetically controlled
process where vessels are formed de novo together with the
surrounding tissue in a manner that is spatially and tem-
porally reproducible. In contrast, neovascularization linked
to different pathological conditions in the adult occurs in
already differentiated tissues and is regulated by inflam-
mation and less predictable liberation of local factors.
Frequently used non-developmental in vivo angiogene-
sis assays such as the CAM [24, 30–32], transparent
chambers [33–35], matrix or sponge implants [22] and the
cornea model [36, 37] all utilize the pre-existing vascula-
ture as a source of vessels that expand into an implanted or
injury-induced matrix. Even though these non-develop-
mental in vivo models are more relevant for pre-clinical
studies of pro- and anti-angiogenic substances, they do not
allow discrimination of functionally perfused vessels from
those with no or low perfusion when classical readouts
such as counting vessels or proliferating endothelial cells
on tissue sections, or measurement of total tissue blood
content, are used [23, 38]. In addition, except for cornea
and grid-based CAM models, none of these assays allow
easy discrimination between new and pre-existing vessels.
The CAM assay is widely used for both developmental
and post-developmental studies of angiogenesis due to easy
access to the vascularized CAM membrane [24, 30, 39]. An
additional advantage is that in many countries animal
license is not needed for chicken embryo experimentation.
The assay is rapid, inexpensive and suitable for large-scale
screening of substances thought to regulate angiogenesis.
However, the normal CAM tissue has a dense capillary
network, which makes it difficult to distinguish new from
pre-existing vessels when applying stimulatory substances
directly on the CAM membrane [24, 25]. In addition, the
membrane is sensitive to slight changes in pH, oxygen
tension and physical or chemical injuries which results in a
remodeling reaction with contraction of the CAM towards
the irritant [24]. This creates a spoke-wheel pattern of
radiating vessels that mistakenly might be interpreted as
new vessels growing towards the stimulus [24, 32].
We have developed an angiogenesis assay that circum-
vents these shortcomings. A provisional gel-matrix of
defined size and composition is placed on the CAM and
vascularized in response to fibroblast growth factor-2
(FGF-2) or platelet derived growth factor-BB (PDGF-BB).
The effects of pro- and anti-angiogenic substances on
neovascularization as well as on pre-existing vessels can be
determined separately as the matrix is separated from the
CAM by a nylon mesh. Neovascularization is quantified
either by binomial scoring or by a semi-automated image
analysis procedure to detect more subtle effects. This in
vivo model has the potential to become a valuable tool in
large scale screening of substances developed with the aim
to regulate angiogenesis.
Materials and methods
Preparation of the gel-holding chamber
A 0.5 cm high tube was cut from a plastic soft drink straw
(5 mm in diameter) and glued with cyanoacrylate in the
middle of a 1.5 9 1.5 cm square of a nylon mesh. Con-
structs were kept for at least 2 h at room temperature for
the glue to harden. Constructs were then silanized for
2 min in Repel-Silane ES PlusOne (Pharmacia), washed
once in isopropanol, twice in 99 % ethanol and twice in
distillated water. Constructs were taken directly from water
and placed on a paraffin film (Parafilm) that had been fixed
in a humidified transparent plastic box. One box held two
15 cm long Parafilm strips and each strip carried two rows
of 10 constructs. The chamber with 40 construct was
incubated for 1 h at 50 C which resulted in a weak fixa-
tion of constructs to the paraffin. Constructs were sterilized
by spraying with 70 % ethanol, dried and kept at room
temperature until preparation of the gel.
Preparation of the fibrin-collagen implant
A 59 concentrated stock of 25 mg/ml fibrinogen was pre-
pared by dissolving lyophilized bovine fibrinogen (Sigma)
in a buffered solution of 107 mM NaCl, 2,700 IU/ml apro-
tinin, 250 mM HEPES pH 8.6 at 4 C. The fibrinogen was
dissolved by vortexing for 5 min and then filtered through
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a 0.45 lm sterile syringe filter, which required approxi-
mately one filter per 5 ml of fibrinogen stock. The fibrin-
ogen was aliquoted, frozen and stored at -80 C for no
longer than 1 month. Collagen-fibrin gels were prepared by
mixing one part of freshly thawed fibrinogen stock solution
with 5 parts ice-cold rat-tail collagen (4 mg/ml, Upstate).
The mixture was vortexed, quickly spun down to remove
air bubbles and 100 ll of the mixture carefully pipetted
into the gel-holding chambers. Gels were then incubated in
a humidified box for 10 min at 37 C to allow collagen to
polymerize before addition of 50 ll of thrombin (2 IU/ml;
Sigma) dissolved in clotting buffer (5 lM CaCl2, 10 lM
MgCl2, 4.5 mg/ml streptomycin, 4.5 mg/ml penicillin,
11.25 mg/ml amphotericin B, 500 lg/ml BSA, 5,000 IU/
ml aprotinin, 50 mM HEPES pH 7.6) and saline or 5 mg/
ml FGF-2 (250 ng/construct). Where indicated FGF-2 was
replaced with PDGF-BB (5 mg/ml, 250 ng/construct),
VEGF (5 mg/ml, 250 ng/construct), or TGF-b (2 mg/ml,
100 ng/construct). After equilibration with the clotting
buffer the theoretical pH of the gel was 7.6 and osmolarity
320 mOsM. Finally, 25 ll of sunflower oil was pipetted on
top of the aqueous media. Oil prevented the gel from
drying and infection during polymerization and incubation
on the CAM and served as a solvent for fumagillin (32 lg),
racemic mixture of thalidomide (2 mg), hydrocortisone
(500 lg), U0126 (50 lg) or wortmannin (1 or 10 lg) as
indicated. The amount of drug added to a construct was
estimated from previously published in vivo experiments
according to an empirical rule where the amount of drug
per construct was three times higher than previously pub-
lished amounts of drug/body weight/day. The reason for
using this higher dose was that we only added the drug
once and did not reiterate during the 6-day incubation
period. The gels were allowed to polymerize over night at
37 C in 95 % humidity. The next day gels were inspected
and only constructs without gel leakage were kept for
CAM implantation.
Calculation of release curves of hydrophobic drugs
Constructs were prepared as described and 2 mg of fluo-
rescein, tetramethylorhodamine or propidium iodide was
mixed with 1 ml of sunflower oil and 25 ll of this mix was
placed on the surface of the clotting buffer that covered the
gel. Each construct was transferred to a well in a 24-well
plate and 1 ml of Ringer solution was added to the bottom
of the well. The plate was placed on a shaker at 37 C and
25 ll samples of the Ringer were collected every
20–30 min and the absorbance of collected samples mea-
sured at the appropriate wavelength for each compound.
The results were plotted on a time scale and linear
regression slopes calculated. Data from two experiments
were pooled and only the linear range of the plot was used
to fit the linear regression.
Gel implantation on the CAM
White Leghorn eggs were incubated at 38 C in 70 %
humidity for 3 days before the air sac was moved from the
egg pole to the egg side by making a punch-hole in the air-sac
pole and one hole in the side of the egg. The side hole was
then taped and eggs were returned to the incubator for
another 9 days. On day 12 of embryo development, the shell
covering the air sac was taped to avoid potentially irritating
shell fragments to fall down on the CAM while cutting a hole
in the shell with scissors. A single construct was then placed
on the CAM through the window in the shell and the opening
immediately taped to avoid membrane drying and infection.
Eggs were then returned to the incubator for additional
6 days and kept at 38 C with 100 % relative humidity to
avoid CAM drying.
Visualization of neovessels
The whole eggs were fixed in 29 concentrated Zn-fixer
(4.5 mM CaCl2, 51.5 mM ZnCl2, 32 mM Zn(CF3CO2)2,
1.5 mM Tris, 38.5 mM glycine, pH adjusted to 6.0; final
osmolarity 340 mosmol/L) for 1 h and constructs then cut out
from the CAM and the plastic tube was removed. This proce-
dure left the fibrin/collagen gel, ingrown tissue with neovessels,
and underlying pre-existing CAM attached to the nylon mesh.
Fixation before tissue manipulation minimizes artifacts due to
tissue injury and preserves the blood content within neovessels
that can later be stained for hemoglobin. Vessels with func-
tional circulation were identified by an intravascular injection
of ink before Zn fixation. To access a vessel for ink injection a
small crack was created and shell fragments carefully peeled
off leaving the pergamon membrane intact. Applying a drop of
sunflower oil increased the transparency of the pergamon
membrane and revealed larger vessels in the CAM and made it
possible to inject a CAM vein with 0.5 ml of colloidal carbon
(India ink). To visualize all blood-containing structures, tissues
were treated with a diaminobenzidine (DAB) solution (15 mM
potassium acetate pH 5.0, 70 % ethanol, 40 mg/ml DAB,
0.3 % H2O2) that permanently stained hemoglobin and
gave erythrocytes a red or brown color that persisted during
subsequent treatment with benzyl benzoate/benzyl alcohol
(BBBA; 1:1). Since DAB cannot diffuse freely through the
thick gel or tissue mass (not shown), the remaining gel was
partially lifted to allow influx of DAB under the gel to come in
direct contact with ingrown vessels that were partially covered
by the gel implant. This staining protocol allowed us to dis-
criminate actively perfused vessels (ink perfused black vessels)
from those with low or no perfusion (DAB stained red or brown
structures). The CAM attached to the mesh underlying the
Angiogenesis (2012) 15:643–655 645
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implant was then photographed to document effects of drugs
on pre-existing vessels. Thereafter the CAM was scraped off
with a scalpel and the neovascular ingrowth on the opposite
side of the mesh was photographed.
Live imaging of vascular permeability
The fibrin/collagen gel was placed on the CAM and after
6 days of incubation the chicken was given an intravas-
cular injection of TRITC-dextran (155 kDa; 100 ll of a
10 mg/ml solution). Vessels growing through the grid were
identified and 10 ll of saline was added to this area. The
neovasculature was imaged for 15 min with time-lapse
microscopy at a frame rate of 1 image per second using a
Leica M205 FA fluorescent stereomicroscope. Then 10 ll
of human VEGF-A (200 ng/ml) was applied and imaging
continued for additional 15 min.
Quantitation and statistical analysis
Vascular ingrowth was scored on a binomial (yes or no)
scale in a double-blinded manner. The results from inde-
pendent experiments were pooled and differences between
treatments were assessed using Fisher exact test with an
a = 0.05 as significance level. To compare subtle differ-
ences in vascular ingrowth, vessel density was measured.
Clarified (BBBA treated) implant tissues with the under-
lying CAM membrane removed were photographed (Nikon
Coolpix 4500) with smallest (fixed) aperture using a
magnification that covered the position of the original
implant. Images (2,272 9 1,704 pixels) were saved as jpg
with highest quality format and processed using Adobe
Photoshop CS with IPTG 5.0 plugins. The process of
analysis was standardized; resolution of images was con-
verted to 300 dpi and vascular structures transformed into a
one-pixel diameter skeleton representation. Vessel density
was calculated by measuring total vessel length that was
divided by the vascularized area. Hemorrhages and other
interfering objects (e.g. shell fragments) were manually
removed before image processing. Differences between
treatments were tested with one-way ANOVA, followed by
post hoc Tukey test for unequal sample sizes (Unequal N
HSD test). For leakage analysis, GraphPad Prism was used
to calculate if the slopes from the control are significantly
different from the VEGF-A group.
Results
Preparation of defined and reproducible matrix implants
A matrix consisting of fibrin and rat-tail collagen type I
was formed in a 0.5 cm high plastic tube that was glued
onto a 1.5 9 1.5 cm piece of a nylon mesh. The tube gave
gels a reproducible size and shape and allowed addition of
substances expected to regulate vascularization (Fig. 1a–c).
Application of a nylon mesh made it possible to distinguish
neovessels growing through the mesh from pre-existing
vessels (Fig. 1f). In addition, the mesh distributed the
weight of the construct more evenly, which minimized
mechanical damage to the CAM (Fig. 1f). Before forming
the gel, the construct was silanized in order to create a non-
sticky surface that allowed the gel to freely contract and
change size during its vascularization on the CAM
(Fig. 1g, h). Water-soluble compounds such as growth
factors were mixed into the clotting buffer that was added
on top of the polymerized gel (Fig. 1b). Finally, a layer of
sunflower oil covered the clotting buffer in the construct,
which created a closed and sterile environment that also
prevented the gel from drying. The oil layer also served as
a solvent for lipophilic substances that were released into
the matrix during incubation on the CAM. A single gel
construct was placed on the CAM at day 12 of embryo
development through a window in the shell of a white
Leghorn egg (Fig. 1e, f). After 6 days of incubation with
the construct the entire egg was fixed in Zn fixer. The
construct was then cut out from the CAM and the plastic
tube removed. This left the fibrin/collagen gel, ingrown
tissue with vessels, and the underlying pre-existing CAM
tissue attached to the nylon mesh (Fig. 1i).
Visualization of implant neovascularization in whole-
mount preparation
The opacity of the gel increased during vascularization,
which impaired detection of ingrown vessels (Fig. 2a).
Blood vessels were therefore stained by treating CAM
explants with a diaminobenzidine (DAB/H2O2) solution that
permanently stained erythrocytes red (Fig. 2a, b). This ves-
sel staining persisted after the tissue was treated with benzyl
benzoate/benzyl alcohol (BBBA), which was used to render
the opaque tissue transparent, and made it possible to visu-
alize the entire neovasculature (Fig. 2b, d). Ink was injected
intravenously to distinguish vessels with functional circu-
lation from those filled with blood, but with no or incomplete
perfusion. Ink is a non-diffusible colloidal stain that marks
perfused vessels black while under- or non-perfused vessels
remain red due to previous staining with DAB (Fig. 2b–d).
Dose–response experiments indicated that FGF-2 dependent
vessel ingrowth does not occur after reducing the amount of
FGF-2 below a certain threshold. The number of inactive
(red stained) vessels was negligible and restricted to mor-
phologically aberrant structures e.g. locally enlarged neo-
vessels or chemically injured pre-existing CAM vessels
(Fig. 2d, compare with Fig. 5e) showing that nearly all
ingrowing vascular structures were functional.
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The optimal nylon mesh was selected by comparing mesh
openings of 100, 300, 600 and 900 lm (not shown). The
degree of vascular ingrowth was similar for all mesh sizes.
However, the 100 lm mesh tended to bend with a non-
uniform attachment to the CAM and the 600 and 900 lm
mesh sizes often injured the CAM due to stiffer nylon
threads. Therefore the 300 lm mesh size was selected.
Implant neovascularization is enhanced by FGF-2
and PDGF-BB but not by VEGF-A
Implanted fibrin-collagen matrices were vascularized in
20 % of cases without addition of growth factors. FGF-2 or
PDGF-BB caused a three to four fold increase in the
number of vascularized implants. Surprisingly, VEGF-A
[4] did not stimulate implant vascularization, while TGFb
had a strong inhibitory effect on spontaneous as well as
FGF-2-induced neovascularization (Fig. 3a). The inability
of human VEGF-A to induce neovascularization was not
related to species differences as we found that hVEGF-A
was recognized by chicken endothelium and induced a
substantial increase in vascular permeability when applied
on neovessels of the vascularized implant as shown by the
TRITC-dextran extravasation assay, which is analogous to
the Miles permeability assay [40] (Fig. 3b, c and Supple-
mentary videos 1 and 2).
Inhibition of angiogenesis can be distinguished
from toxic effects on pre-existing vessels
A selection of substances known to inhibit angiogenesis in
vivo was tested for their ability to inhibit FGF-2 induced
neovascularization of gel implants on the CAM. Both
ingrowth of neovessels and potentially toxic effects of the
drugs on pre-existing vessels in the CAM under the implants
were analyzed (Fig. 4a, b). Vascular ingrowth was scored on
Fig. 1 Technical outline of the implant vascularization assay. a A
plastic straw was glued onto a nylon mesh and a fibrinogen-collagen
solution applied in the straw. b The implant was covered with clotting
buffer and plant oil. In this image the clotting buffer is stained black.
c The polymerized gel does not stick to the silanized construct, which
allowed the straw to be removed without affecting the gel. d Blood
vessels of 12-days CAM were stained with DAB/H2O2. Superficial
dense capillary network (arrowheads) is supported by larger feeding
vessels (V). e The CAM membrane was exposed by cutting a window
in the shell of White Leghorn eggs at day 12 of incubation. f A
construct placed on the CAM. The nylon mesh separated the pre-
existing CAM from the gel and distributed the weight over a larger
tissue area. g Control and FGF-2 h containing constructs after 6 days
of incubation. Parallel to vascular ingrowth gels were partially
digested, contracted by invading cells and the gel opacity increased.
i After whole-egg fixation, the constructs with the underlying CAM
were excised and the plastic tubes detached
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a binomial (yes or no) scale in a double-blinded manner.
Fumagillin [41] and the MEK inhibitor U0126 [42] inhibited
neovascularization while thalidomide [43] had no effect
on vessel growth using this method of quantification
(Fig. 4a). None of these substances affected pre-existing
vessels (Fig. 4b). PD173074, which is an FGFR1, FGFR3
and a weak VEGFR2 inhibitor, reduced FGF-2-dependent
implant vascularization in a dose dependent manner but did
not affect PDGF-dependent vessel growth. This experiment
showed that an inhibitor added to the gel is released over
time and that dose response relationships can be established
(Fig. 4c). To further characterize release kinetics of
hydrophobic substances from the oil phase we mixed the
colored hydrophobic chemicals fluorescein and tetrameth-
ylorhodamin (TMR) (solubility in water for both is lower
than 50 lg/ml) and water soluble propidium iodide (solu-
bility in water 1–10 mg/ml) in oil and applied the oil mix-
ture to the construct on the surface of the clotting buffer
covering the gel. These chemicals have similar molecular
masses as the hydrophobic inhibitors used in this study. The
speed of release was calculated during the early linear phase
with the assumption that the release of the drug from an
implant on the CAM will not reach saturation as an excess of
the drug is cleared from the tissue due to the circulating
blood. Both hydrophobic compounds were released at
similar speeds, while the water-soluble propidium iodide
was released from oil at a 5 times higher rate. Assuming that
the release of compounds from the oil phase is dependent on
their water solubility the release speed of hydrophilic pro-
pidium iodide (200 ng/min) should constitute the upper
limit for the speed of release for any water insoluble com-
pound. The average value of the release slopes for fluores-
cein and TMR was 48.5 ng/min and we used this value to
calculate approximate complete release times for com-
pounds used in this study. For 2 mg of thalidomide the
predicted release time was 670 h (25 days), for 32 lg of
fumagillin 12 h, for 500 lg of hydrocortisone 180 h
(7.5 days) and for 50 lg of U0126 18 h. Except for thalid-
omide all these compounds inhibited implant neovascular-
ization even though fumagillin and U0126 should
completely diffuse from the construct within the first day of
incubation on CAM. Thalidomide was present in excess for
the entire time of implant incubation on CAM but did not
reduced vascularization using the yes/no scoring method.
This was in contrast to the PI3K inhibitor wortmannin [44],
which blocked matrix vascularization (Fig. 5a) but also
exerted a toxic effect on normal CAM vessels causing vessel
occlusion and hemorrhages already 24 h after implantation
(Fig. 5b). Lowering the dose of wortmannin only reduced
the area of the injury but had no effect on the mode of
toxicity (Fig. 5c). Hydrocortisone [45] inhibited but did not
block neovascularization (Figs. 4a, 5d) and caused thinning
Fig. 2 Visualization of neovessels and testing their functionality by
erytrocyte staining and i.v. ink perfusion. a The remaining opaque gel
covered the ingrown vasculature in samples that had been fixed and
stained with DAB/H2O2. b Clarification with BBBA increased tissue
and gel transparency revealing the ingrown DAB/H2O2 stained
neovascular network. c, d To distinguish vessels with functional
circulation from those with no or incomplete perfusion an intravenous
injection of ink was performed before fixation and staining with
DAB/H2O2. c Control and d FGF-2. The shape of transparent gel cap
is visualized due to differences in refraction indices between air and
BBBA. e Induction of neovascularization by FGF-2 is bipolar with no
stimulation of vessels ingrowth at lower doses of FGF-2
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Fig. 3 Effects of growth factors on neovascularization. a Growth
factors were tested for their abilities to stimulate vascularization of a
fibrin-collagen matrix implanted on the CAM and samples scored in a
binomial manner (yes or no). FGF-2 (250 ng) and PDGF-BB (250 ng)
induced vascularization, while human VEGF-A (250 ng) had no
effect. TGF-b (100 ng) blocked spontaneous and reduced FGF-2-
induced vessel ingrowth. b, c hVEGF-A induced TRITC-dextran
extravasation from the implant neovasculature. 6 days after
implantation 155 kDa TRITC-dextran was injected i.v. and neoves-
sels that grew through the grid were first imaged for 15 min (12 min
shown) after application of saline (control) and then for an additional
15 min (12 min shown) after stimulation with hVEGF-A (VEGF).
Basal level of leakage from the neovessels was robustly increased
after application of hVEGF-A. Note that in (b) the VEGF-A effect is
underestimated as fluorescence signal quickly reached the saturation
level (see Supplementary videos 1 and 2)
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of vessels in the normal CAM vasculature but unlike wort-
mannin did not cause hemorrhages (Fig. 5e, f). Interest-
ingly, transforming growth factor b (TGF-b) blocked
spontaneous and FGF-2 induced implant vascularization
(Figs. 3a, 5g) and also increased the diameters of the
feeding CAM vessels located directly under the implant
(Fig. 5h, i).
Quantification of vessel density
To distinguish between different vascularization levels in
the implant, we developed a technique to measure vessel
density in the ingrown tissue. The calculated values reflect
both the length and the density of neovessels. Successive
stages of image processing are presented in Fig. 6a–d. By
using this quantification method we found that thalidomide,
which did not block neovascularization when vasculariza-
tion was scored in a binomial manner (Fig. 4a) indeed
reduced neovessel density in FGF-2 stimulated implants
(p \ 0.05; Fig. 6e). We also evaluated assay reproduc-
ibility by using two different methods of vessel detection
with either erythrocyte staining (with DAB/H2O2) or by
intravascular ink injection, which showed that assay vari-
ability was low as neither controls (p \ 0.707) nor FGF-2-
stimulated (p \ 0.816) groups differ between independent
experiments and different detection methods. These results
confirm that blunt-ended and blood-filled vascular struc-
tures, either growing or regressing, can be neglected in the
total vascular count.
Discussion
Studies of angiogenesis are hampered by difficulties in
distinguishing neovessels from pre-existing vessels, inabil-
ity to discriminate inhibition of angiogenesis from vessel
regression and problems related to quantification of the
angiogenic response as well as determining the functionality
of neovessels. In this report we describe an in vivo angio-
genesis assay that circumvents these problems. We verified
this model by testing known activators and inhibitors of
angiogenesis with simultaneous assessment of their effects
on pre-existing blood vessels. We have previously reported
that the sequence of physiological events during neovessel
ingrowth in this type of assay most closely reflects formation
of vessels in granulation tissue during tissue healing with
invasion of leukocytes, ingrowth of proto/myofibroblasts
and formation of functional capillaries [31, 46].
The use of a nylon mesh to separate the pre-existing
vasculature from neovessels entering the implant has pre-
viously been described [32, 47] and in this report we further
expand the use of a mesh by combining it with a gel chamber
which produces gel matrices with a reproducible size, shape
and composition. The size of the mesh surface was increased
10 times as compared to the original publication by Nguyen
[32] in order to distribute the weight of the implant over a
larger surface area and to minimize mechanical damage to
the CAM. The assay described in this report has several
advantages as compared to other methods that use the CAM
as a source of blood vessels for vascularization of an
implanted matrix [32, 47, 48]. Since water-soluble factors
are added to the gel after it has been polymerize in vitro, the
matrix composition is consistent between different experi-
ments and treatment groups. In vitro gel formation also
reduces the variability of the final matrix that results from
varying conditions during polymerization that occurs when
matrices are formed directly on the CAM. Growth factors
are, at least initially, protected from proteolytic degradation
by addition of a high concentration of the serine protease
inhibitor aprotinin. Application of plant oil as the last layer
covering the gel and clotting buffer sealed the implant and
protected it from drying and potential infections. Water-
insoluble drugs could be dissolved in the oil phase which
eliminated the need for using toxic organic solvents like
DMSO. These organic solvents chemically damage the
tissue which results in an artificial spoke-wheel pattern of
vessels that can be misinterpreted as neovascular ingrowth
(Supplementary Fig. 1). The use of a mesh made it pos-
sible to unambiguously distinguish ingrowing neovessels
from the pre-existing vasculature, as vessels that appear
above the grid by definition were neovessels. This is in
contrast to e.g. the sponge implantation assay where
distinction between new and pre-existing vessels is a
recognized limitation [48].
The need for using of non-avian growth factors is a
limitation for this and all other CAM based assays since
mammalian proteins might not be recognized by the cor-
responding chicken receptors. Hence, the lack of an effect
of human-derived cytokines has to be validated using other
chicken models such as the ex vivo myofibroblast sprouting
assay [49] or, as presented in this report, a chicken based
vascular permeability assay. Since not all cytokines result
in a biological response, the potential biological incom-
patibility of tested compounds constitutes a drawback of
our model. The amount of growth factors per implant used
in this study (250 ng/implant) is in the same range as used
in similar assays e.g. 250–500 ng FGF-2 and 150 ng
VEGF-A for gel implants on CAM [46, 47], 30 lg FGF-2
and 3 lg VEGF-A per implant in subcutaneous or cranial
window assays in mice [50], 250 ng VEGF-A or FGF-2 per
cornea pocket in rats [51], 200 ng of VEGF-A and FGF-2
on developmental CAM models [52] and 3.3 lg per implant
of VEGF-A, PlGF-1, PlGF-2 and VEGF-C also using a
developmental CAM assay [53]. Since 250 ng FGF-2 per
construct induced implant vascularization and had no
obvious adverse effect on animal well-being we decided to
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Fig. 4 Effects of pro- and anti-angiogenic factors on neovessel ingrowth
and on the pre-existing vasculature. a FGF-2 induced vascularization was
significantly inhibited by fumagillin (32 lg), hydrocortisone (500 lg)
and U0126 (50 lg) while thalidomide (2 mg) did not reduced the number
of vascularized implants. *p \ 0.05, ns non-significant. b Representative
images of the effects of various treatments on implants vascularization
and underlying CAM vasculature on. Gel implants with FGF-2 and
angiogenesis inhibitors as indicated were applied on the CAM membrane
and incubated for 6 days. Ink was injected intravenously prior fixation
and samples were then clarified with BBBA. Pre-existing vessels in the
CAM under the implant mesh were photographed and then scraped off to
enable visualization of gel-ingrowing vessels. The ‘‘spoke-wheel’’
pattern in the CAM under the implanted mesh is the result of tissue
contraction. c The FGFR1 and FGFR3 inhibitor PD173074 dose
dependently inhibited FGF-2 but not PDGF-BB-induced neovasculari-
zation. d Release curves for hydrophobic (fluorescein and TMR) and
water-soluble propidium iodide from oil. The average speed of release for
fluorescein and TMR was 48.5 ng/min
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use this dose for testing the effects of other growth factors as
they have similar dissociation constants (Kd). Neovascu-
larization in response to FGF-2 was binomial i.e. reducing
the amount of FGF-2 from 500 to 50 ng per implant resulted
in a complete lack of FGF-2-dependent neovascularization.
We therefore decided to use a binomial yes/no scoring
system for the initial quantification of the angiogenic
response.
Visualization of the entire neovasculature is crucial for
any in vivo angiogenesis assay. We describe a whole-mount
staining protocol where erythrocytes were stained with
DAB/H2O2 and the tissue is subsequently clarified with
BBBA, which made it possible to visualize the entire neo-
vasculature using a regular dissection stereomicroscope.
The staining procedure is relatively fast, allowing quick
binomial quantification of the angiogenic response and
hence is suitable for large scale screening, in contrast to e.g.
labor-intensive detection of endothelial markers in tissue
sections. Combined injection of colloidal carbon and visu-
alization of all blood containing structures by staining of
hemoglobin was used to distinguish functional vessels
from those with low or no perfusion. This provided a fast
functional analysis of ingrowing vessels. Qualitative and
quantitative analysis of double stained vascular ingrowth
showed that a majority of neovessels were ink-perfused and
thus properly integrated with the circulation. Live visuali-
zation of ingrowing neovessels can also be performed by
fluorescent microscopy after an intravascular injection of
TRITC-dextran. We show that this method can also be used
to study changes in vascular permeability analogous to the
Miles assay.
Quantification of neovascularization based on binomial
scoring is sufficient for analyzing strong biological effects.
If no differences between tested groups could be identified
with the scoring method, a more labor intensive quantitative
approach could be used where measurement of vessel
Fig. 5 Effects of hydrocortisone, wortmannin and TGF-b on pre-
existing vasculature. a–c Wortmannin (10 lg) blocked matrix vascu-
larization (not shown) but also destroyed the pre-existing vascular
network under the implanted gel (a). The toxic effect was apparent
already 24 h (b) after implantation and was manifested by extensive
hemorrhages and vessel occlusion (red vessels are not perfused with
i.v. injected ink). It was not possible to distinguish toxic from
inhibitory effects of wortmannin since 10-times lower dose (1 lg)
was still toxic to pre-existing vessels (f), although the effect was
limited to the central part of the CAM located under the implant. d–
f Hydrocortisone (0.5 lg) inhibited neovascularization (a) and caused
thinning of the pre-existing vessels in CAM underlying the implant
without blocking vessel perfusion (e, f). g–i TGF-b (100 ng) inhibited
spontaneous implant neovascularization (g) and caused enlargement
of pre-existing vessels (h, i). Arrowheads mark the position of the gel.
a–f vessels perfused with i.v. ink injection and stained with DAB/
H2O2, g–i vessels only stained with DAB/H2O2
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density could detect subtle changes in the neovasculature.
Only when there is no difference after quantification of
vessel density that the conclusion ‘‘no inhibition’’ can safely
be drawn when analyzing an angiogenesis inhibitor candi-
date. One example of this approach is thalidomide that only
after measuring vessel density was revealed to have an anti-
angiogenic effect. The quantification technique had low
intra-experimental variation as the same groups (control vs.
FGF-2) did not differ between experiments even though two
different vessel-staining techniques were used.
The inability of VEGF-A to induce angiogenesis in this
assay might have several explanations. One of the most
profound effects of VEGF-A is increasing vascular per-
meability with extravasation of plasma and formation of a
provisional fibrin matrix [40]. However, in the CAM model
described in this report fibrin is already provided in the
applied matrix. Furthermore, our assay was designed to
study the isolated effect of a growth factor in the absence of
tissue injury and a growth factor supplemented-provisional
matrix is therefore applied on unharmed tissue. This is in
contrast to other angiogenesis assays where surgery is used
to apply VEGF-A like the pocket cornea assay, the skin
chamber assay or the matrigel plug assay [21, 23]. Finally,
the inability of VEGF-A to induce angiogenesis in CAM
implants is in agreement with previous studies [47, 56].
The assay has a high capacity and we routinely per-
formed two experiments per week with 240 eggs each.
Experiments can be performed by a single trained
technician and does not require sophisticated or expensive
equipment. It is sufficient to have 15–20 embryos per
experimental group in order to reach statistical significance
if the effect is strong. Most of the times the binomial
scoring system is sufficient, which makes quantitation
simple and fast and results can be statistically tested (Fisher
exact, v2 test).
The assay described in this report permits parallel
investigation of effects on neovascularization and on the
pre-existing vasculature. Since toxic effects of pharmaco-
logical compounds on the normal vasculature might cause
life threatening hemorrhages, this might provide valuable
information during the pre-clinical testing phase. The
angiogenesis inhibitor fumagillin and an inhibitor of the
mitogen-activated protein kinase pathway (U0126) inhib-
ited angiogenesis without affecting pre-existing vessels.
Hydrocortisone has been shown to have an anti-angiogenic
potential by affecting basal membrane composition [57]
and was found here to reduce implant neovascularization
and also caused thinning of pre-existing vessels. In con-
trast, the PI3K inhibitor wortmannin not only blocked
implant vascularization but also had an immediate and
strong toxic effect on normal CAM vessels causing hem-
orrhages and regression of vessels. The high toxicity on
normal tissue most likely precludes the use of this com-
pound in anti-angiogenic therapies. TGF-b did not induce
implant neovascularization but blocked spontaneous and
FGF-2-induced vessel ingrowth which is in agreement with
Fig. 6 Semi-automated quantification of neovessel density. a–d
Successive stages of image processing using Adobe Photoshop and
IPTK plugins (Reindeer Graphics). Image resolution was set to 300
dpi and the raw image (a) was auto-leveled and sharpened (b) which
was followed by edge enhancements (Stochastic edge plugin) from
which surface iso-brightness lines were drawn (c). After dilatation by
3 pixels with the ranking filter, gray-scale branches were skeletonized
(d) and the total skeleton length and its area were then calculated.
e Thalidomide reduced neovessel density in FGF-2-stimulated
implants. Different vessel staining techniques (DAB/H2O2 and i.v.
ink injection) have no effect on calculated vessel density. Box-95 %
percentile, whisker-Min-Max
Angiogenesis (2012) 15:643–655 653
123
previous studies [58]. In addition TGF-b caused enlarge-
ment of pre-existing macrovessels underlying the implant.
A number of pro- and anti-angiogenic molecules have
entered clinical trials for a variety of diseases. However, in
spite of promising results obtained from animal models,
many therapies have failed when applied in the clinic.
These discrepancies between bench and bedside suggest
that current in vivo angiogenesis assays should be
improved in order to better understand mechanisms of non-
developmental angiogenesesis during tissue vascularization
and repair. This in turn could aid in development of
reagents that can specifically target neovascularization.
The assay described in this report was developed in order
to meet the suggested requirements for an optimal in vivo
angiogenesis assay [19, 20, 22, 23].
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